Randomized phase II study exploring better regimen of hepatic arterial infusion chemotherapy for the patients with advanced hepatocellular carcinoma

Randomized phase II study exploring better regimen of hepatic arterial infusion chemotherapy for the patients with advanced hepatocellular carcinoma - Randomized phase II study exploring better regimen of hepatic arterial infusion chemotherapy for the patients with advanced hepatocellular carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021469

Enrollment

125

Registered

2016-03-16

Start date

2016-03-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

HAIC using FP regimen HAIC using CDDP regimen

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: clinically diagnosed as hepatocellular carcinoma; presence of intrahepatic lesion; unsuitable for local therapy; unsuitable for standard therapy including sorafenib; Child-Pugh score <=8; ECOG Performance status <=2; preservation of major organ function; written informed consent

Exclusion criteria

Exclusion criteria: technically unsuitable for HAIC; extrahepatic lesion; refractory ascites or pleural effusion, history of hepatic encephalopathy, risky varices; double cancer; metastases to central nervous system; severe complication; pregnant or lactating women, or women of childbearing potential; mental disorder; allergy for fluorouracil, cisplatin, or contrast agent of CT or/and MRI

Design outcomes

Primary

Measure	Time frame
Progression-free survival	—

Countries

Japan

Contacts

Public ContactTatsuya Yamashita

Kanazawa University Hospital Department of Gastroenterology

ytatsuya@m-kanazawa.jp076-265-2235

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026